Isomorphic Labs has raised $5 billion that it intends to spend pushing its AI-designed drug candidates into clinical trials, TechCrunch reports.

The round arrives about two weeks after reports put the Google DeepMind spinoff's valuation at roughly $50 billion — a price attached to a company that still has no approved medicine. That gap between valuation and clinical proof is exactly what the new capital is meant to close: trials are the stage at which AI-discovered molecules either back up years of machine-learning promise or fail.

Founded in 2021 as a London-based spin-out of DeepMind — the lab behind AlphaFold's protein-structure predictions — Isomorphic Labs has positioned itself as a platform company, designing molecules computationally and moving them toward the clinic through partnerships with drugmakers.

Getting candidates into human trials is the expensive, slow phase of drug development, where most programs stall. A war chest of $5 billion gives the company room to fund several shots on goal rather than a single lead program.

The timing is pointed. Our own coverage two weeks ago framed the stakes plainly: the flagship of AI drug discovery was being priced at $50 billion with no approved drug. The new money is a bet on future trials, not on past results — a field that has yet to deliver an approved therapy discovered end to end by artificial intelligence.